Coverart for item
The Resource Emerging Targets for Drug Addiction Treatment

Emerging Targets for Drug Addiction Treatment

Label
Emerging Targets for Drug Addiction Treatment
Title
Emerging Targets for Drug Addiction Treatment
Creator
Subject
Genre
Language
eng
Summary
In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid abuse, as well as non-drug addictions, with an emphasis in novel pharmacological interventions and potential receptor targets recently identified. The intended audience of this exciting selection is broad, encompassing clinicians, researchers and graduate students who seek advanced knowledge and up-t
Member of
Cataloging source
EBLCP
http://library.link/vocab/creatorName
Canales, Juan
Dewey number
  • 362.29
  • 616.86
Index
index present
LC call number
RC563
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
Series statement
Substance Abuse Assessment, Interventions and Treatment
http://library.link/vocab/subjectName
  • Drug addiction
  • PSYCHOLOGY
  • SELF-HELP
  • Drug addiction
  • Drogenabhängigkeit
  • Pharmakotherapie
  • Arzneimittelentwicklung
Label
Emerging Targets for Drug Addiction Treatment
Instantiates
Publication
Note
Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)
  • 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy
  • 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES
  • 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES
  • Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES
Control code
898103608
Dimensions
unknown
Extent
1 online resource (240 pages).
Form of item
online
Isbn
9781620819548
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)898103608
Label
Emerging Targets for Drug Addiction Treatment
Publication
Note
Chapter 6: PSYCHOSOCIAL AND PHARMACOLOGICAL TREATMENTS FOR BEHAVIORAL ADDICTIONS
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)
  • 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy
  • 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES
  • 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES
  • Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES
Control code
898103608
Dimensions
unknown
Extent
1 online resource (240 pages).
Form of item
online
Isbn
9781620819548
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Specific material designation
remote
System control number
(OCoLC)898103608

Library Locations

    • Thomas Jefferson LibraryBorrow it
      1 University Blvd, St. Louis, MO, 63121, US
      38.710138 -90.311107
Processing Feedback ...